Latest news with #SYK
Business Insider
a day ago
- Business
- Business Insider
Stryker awarded $450M Defense Logistics Agency contract modification
Stryker (SYK) has been awarded a maximum $450M modification exercising the five-year option period of a five-year base contract with one five-year option period for patient monitoring and capital equipment. This is a fixed-price with economic-price-adjustment, indefinite-delivery/indefinite-quantity contract. The ordering period end date is July 16, 2030. Using customers are Army, Navy, Air Force, Marines Corps, and federal civilian agencies. Type of appropriation is fiscal 2025 through 2030 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
6 days ago
- Business
- Yahoo
What to Expect From Stryker's Next Quarterly Earnings Report
Portage, Michigan-based Stryker Corporation (SYK) operates as a medical technology company that develops, manufactures, and markets specialty surgical and medical products. Valued at $148.7 billion by market cap, the company's products include implants, surgical, neurologic, ear, nose and throat and interventional pain equipment, endoscopic, surgical navigation, digital imaging systems, as well as patient handling and emergency medical equipment. The Medtech giant is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect SYK to report a profit of $3.06 per share on a diluted basis, up 8.9% from $2.81 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. This Underdog AI Stock Just Got a New Street-High Price Target Texas Just Passed Quantum Computing Legislation. How Should You Play IONQ Stock Here? 'The Most Patriotic Thing You Can Do Is Not Pay the IRS' Says Grant Cardone as OBBBA Signed into Law — Here's How Much You'll Save Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect SYK to report EPS of $13.35, up 9.5% from $12.19 in fiscal 2024. Its EPS is expected to rise 11% year over year to $14.82 in fiscal 2026. SYK stock has outperformed the S&P 500 Index's ($SPX) 12.3% gains over the past 52 weeks, with shares up 16.8% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 6.5% dip over the same time frame. SYK thrives on growing procedural volumes and strong capital product demand. On May 1, SYK reported its Q1 results, and its shares closed up more than 1% in the following trading session. Its adjusted EPS of $2.84 exceeded Wall Street expectations of $2.73. The company's revenue was $5.9 billion, exceeding Wall Street forecasts of $5.7 billion. SYK expects full-year adjusted EPS in the range of $13.20 to $13.45. Analysts' consensus opinion on SYK stock is bullish, with a 'Strong Buy' rating overall. Out of 28 analysts covering the stock, 19 advise a 'Strong Buy' rating, two suggest a 'Moderate Buy,' and seven give a 'Hold.' SYK's average analyst price target is $431.77, indicating a potential upside of 10.1% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
Jim Cramer on Stryker Corporation (SYK): 'I Don't Like It Enough'
We recently published a list of . In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other stocks that Jim Cramer discusses. When a caller asked about Stryker Corporation (NYSE:SYK), Cramer replied: 'I like Stryker, but you know, I don't like it enough. I don't like it as much as if it was Intuitive Surgical. That's the one that I thought we should buy. ISRG.' A medical team wearing surgical masks and gloves carrying out a hip or knee joint replacement surgery with the help of surgical navigation systems. Stryker (NYSE:SYK) is a medical technology company that supplies products like joint implants, spinal systems, surgical tools, patient safety equipment, neurosurgical devices, and other healthcare technologies. Toward the end of March, talking about the company, Cramer stated: 'Stryker is a good company and I think that a medical device company in this environment will do well. Now, there's some people that are gonna say, listen, they're going to be tariffs on that company. I'm not sure whether they'll really matter. I think Stryker works in an environment where we're putting 25% tariffs on all foreign cars. As I've been saying to you, Germany, Japan and Korea have to pay. I've been saying it and saying and saying it and it happened tonight. And people say, why didn't we know? I don't know what else I could do.' Overall, SYK ranks 10th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of SYK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SYK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
27-05-2025
- Business
- Yahoo
Jim Cramer on Stryker Corporation (SYK): 'I Don't Like It Enough'
We recently published a list of . In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other stocks that Jim Cramer discusses. When a caller asked about Stryker Corporation (NYSE:SYK), Cramer replied: 'I like Stryker, but you know, I don't like it enough. I don't like it as much as if it was Intuitive Surgical. That's the one that I thought we should buy. ISRG.' A medical team wearing surgical masks and gloves carrying out a hip or knee joint replacement surgery with the help of surgical navigation systems. Stryker (NYSE:SYK) is a medical technology company that supplies products like joint implants, spinal systems, surgical tools, patient safety equipment, neurosurgical devices, and other healthcare technologies. Toward the end of March, talking about the company, Cramer stated: 'Stryker is a good company and I think that a medical device company in this environment will do well. Now, there's some people that are gonna say, listen, they're going to be tariffs on that company. I'm not sure whether they'll really matter. I think Stryker works in an environment where we're putting 25% tariffs on all foreign cars. As I've been saying to you, Germany, Japan and Korea have to pay. I've been saying it and saying and saying it and it happened tonight. And people say, why didn't we know? I don't know what else I could do.' Overall, SYK ranks 10th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of SYK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SYK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds
Medical technology company Stryker (NYSE:SYK) announced better-than-expected revenue in Q1 CY2025, with sales up 11.9% year on year to $5.87 billion. Its non-GAAP profit of $2.84 per share was 4% above analysts' consensus estimates. Is now the time to buy SYK? Find out in our full research report (it's free). Revenue: $5.87 billion vs analyst estimates of $5.68 billion (11.9% year-on-year growth, 3.2% beat) Adjusted EPS: $2.84 vs analyst estimates of $2.73 (4% beat) Adjusted EBITDA: $1.45 billion vs analyst estimates of $1.42 billion (24.7% margin, 2% beat) Adjusted EPS guidance for the full year is $13.33 at the midpoint, missing analyst estimates by 1% Operating Margin: 14.3%, down from 18.5% in the same quarter last year Free Cash Flow Margin: 2.2%, up from 0.7% in the same quarter last year Organic Revenue rose 10.1% year on year, in line with the same quarter last year Market Capitalization: $149.9 billion Stryker's first quarter results reflected healthy demand across both its MedSurg & Neurotechnology and Orthopaedics divisions, with management highlighting double-digit growth in its U.S. trauma, extremities, neurocranial, and surgical technologies segments. CEO Kevin Lobo emphasized the outperformance of new product platforms, especially the Mako robotic system and Pangea trauma plating system, as key contributors to market share gains. Management also pointed to continued strength in international markets, particularly Australia, New Zealand, Japan, and Europe, as a foundation for ongoing growth. Looking ahead, Stryker's 2025 guidance reflects the company's expectation for continued high-single-digit organic sales growth, while acknowledging several headwinds. CFO Preston Wells noted that tariffs—estimated to impact costs by $200 million this year—will require ongoing mitigation through pricing, supply chain optimization, and disciplined spending. Management cited strong order backlogs and robust demand for capital equipment as supportive factors, but recognized supply chain disruptions in the medical business and the need to integrate recent acquisitions like Inari Medical as considerations for the remainder of the year. Stryker's management attributed the quarter's performance to broad-based demand, new product uptake, and successful execution in core and emerging markets. The following insights summarize the major drivers behind the company's recent financial results: Robotic Surgery Momentum: The Mako robotic platform set a Q1 record for installations, with high utilization rates globally. Management expects continued growth in hips and knees as Mako expands into new indications and geographies. Product Innovation Pipeline: Recent launches, such as the LIFEPAK 35 defibrillator and the Pangea trauma plating system, drove meaningful sales growth. LIFEPAK 35 is set to expand into Europe and Japan, while Pangea will enter Australia and Canada this year and Japan in 2026. International Expansion: Stryker underscored strong growth in Australia, New Zealand, Japan, and Europe, citing these markets as significant future catalysts. The company expects regulatory delays to cause a lag between U.S. and international product uptake, but sees a multi-year runway for international sales. M&A and Portfolio Optimization: The acquisition of Inari Medical was completed, integrating into the vascular division. Stryker also finalized the sale of its U.S. Spinal Implants business, sharpening its strategic focus and capital allocation. Capital Equipment Demand: Management reported double-digit growth across capital businesses and stated that hospital capital spending remains robust, with a healthy order backlog and no current signs of a slowdown. Management expects Stryker's growth to be shaped by ongoing product launches, international expansion, and efforts to offset tariff-related cost pressures. The company's outlook is rooted in strong procedural demand, but it faces operational and macroeconomic uncertainties. Tariff Mitigation Efforts: Stryker plans to counteract the estimated $200 million tariff impact through pricing strategies, expense discipline, and supply chain optimizations. CFO Preston Wells noted that gross and operating margin improvement will depend on successfully executing these measures. Capital Equipment Backlog: The elevated order book for capital equipment is expected to support sales growth through the year, with management citing a six-month visibility into demand. Integration of Acquisitions and Divestitures: The performance of newly acquired Inari Medical and the transition of the U.S. Spinal Implants business out of the portfolio are expected to influence both revenue growth and margin profiles in coming quarters. Marcus Robert (JPMorgan): Pressed on how Stryker will absorb the $200 million tariff impact and what mitigation levers are most effective. Management cited sales momentum, pricing, and discretionary spending as key tools. Larry Biegelsen (Wells Fargo): Asked about the sustainability of operating margin expansion despite tariffs, with Preston Wells clarifying that margin gains will come from both gross margin and operating expense initiatives. Joanne Wuensch (Citi): Inquired about the ongoing integration of Inari Medical and whether there were any surprises post-acquisition. Management reported favorable early results and cultural alignment. Ryan Zimmerman (BTIG): Sought details on the international hip business's growth durability, with CEO Kevin Lobo attributing strong results to recent acquisitions and pending product launches in Europe and Asia-Pacific. Travis Steed (Bank of America): Questioned the details and geographic exposure of the tariff impact, as well as mitigation strategies for 2026. Management said future plans remain flexible due to the changing environment. In the coming quarters, the StockStory team will closely monitor (1) the rollout and adoption pace of new products such as Mako 4 and LIFEPAK 35 in both U.S. and international markets, (2) Stryker's ability to offset tariff-related cost pressures through pricing and operational efficiency, and (3) ongoing strength in capital equipment demand and procedural volumes globally. Additionally, we will watch for integration milestones with Inari Medical and any updates regarding regulatory changes or supply chain disruptions. Stryker currently trades at a forward P/E ratio of 28.4×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
